REVIEW article
Front. Immunol.
Sec. Vaccines and Molecular Therapeutics
PCV20 in Pediatric Pneumococcal Prevention: Expanded Coverage, Remaining Challenges
Provisionally accepted
- 1Universita degli Studi di Milano, Milan, Italy
- 2Universita degli Studi di Parma, Parma, Italy
- 3Clinica Pediatrica, Ospedale Universitario di Parma, Parma, Italy
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Pneumococcal conjugate vaccines (PCVs) have substantially reduced the global burden of Streptococcus pneumoniae infections in children, yet serotype replacement and variability in immunogenicity continue to challenge long-term effectiveness. The recent introduction of the 20-valent vaccine (PCV20), which adds seven serotypes to those covered by PCV13, represents an important advance as these additional serotypes—such as 8, 10A, 11A, 12F, 15B, 22F, and 33F—are now recognized as significant contributors to invasive and noninvasive pneumococcal disease. To evaluate the potential and limitations of PCV20, we conducted a systematic literature search across PubMed, Scopus, and Web of Science through July 2025, supplemented by manual reference screening, including randomized trials, observational studies, systematic reviews, meta-analyses, and official reports from WHO, CDC, EMA, and FDA. Current evidence indicates that PCV20 elicits broadly noninferior immune responses compared to PCV13, though weaker responses have been observed for specific serotypes, notably 3, 6B, 9V, 19A, and 23F. Mathematical models suggest PCV20 could prevent thousands of additional pneumococcal cases annually compared with PCV13 or PCV15, but other analyses predict increased breakthrough infections, particularly under reduced-dose regimens. The vaccine's effectiveness may also be limited by the potential for new serotype replacement, and concerns persist regarding its performance in 2+1 or 1+1 schedules, with regulatory agencies currently approving only the 3+1 regimen. These findings highlight PCV20 as a promising step in pneumococcal prevention but not a definitive solution. Continued surveillance, real-world effectiveness studies, and accelerated development of next-generation higher-valency vaccines will be essential to sustain and expand protection against pneumococcal disease in children.
Keywords: clinical effectiveness, Immunogenicity, Next-generation vaccines, PCV20, pneumococcal conjugate vaccines, Serotype replacement, Streptococcus pneumoniae
Received: 17 Sep 2025; Accepted: 15 Dec 2025.
Copyright: © 2025 Principi, Argentiero, Campana and Esposito. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Susanna Maria Roberta Esposito
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.